Biotechnology
BioMed Technology Funded by Alibaba Hong Kong Entrepreneurs Fund, Gobi and TIMC to Realise Precision and Personalised Gut Microbiome Management for Wellness
HONG KONG, April 20, 2023 /PRNewswire/ -- BioMed Technology Holdings Limited (BioMed),Hong Kong's leading microbiome startup, has raised USD 2 million in its latest oversubscribed seed round from Alibaba Hong Kong Entrepreneurs Fund (AEF), Gobi Partners GBA and The International Medical Co. Ltd. ...
2023-04-20 16:15
4491
CBC GROUP AND MUBADALA CO-LEAD US$315 MILLION FUNDRAISING ROUND FOR HASTEN BIOPHARMA
Proceeds raised will be used to fund future acquisitions, and fuel business development of innovative pipeline assets SINGAPORE, April 20, 2023 /PRNewswire/ -- CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm headquartered inSingapore, and Hasten Biopharmaceutic Company Lim...
2023-04-20 13:00
2220
Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-20 08:00
1940
Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 20, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-20 08:00
4060
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
SAN DIEGO, April 19, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company's high pot...
2023-04-19 20:05
1951
Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses
CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM), announced today it has entered into a collaboration agreement w...
2023-04-19 08:45
2006
AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting
SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time,
ImmVira presented preclinical study results of CAR-T enabler oHSV product
MVR-7011 through poster publication at the American Association for Cancer
Research ("AACR") annual meeting.
2023-04-19 08:29
1733
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
* New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate * Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT-207 this year SEONGNAM, South Korea and CAMBRIDG...
2023-04-19 07:00
1792
South Korean Biotech, ToolGen Leads the Development of Numerous Cutting-Edge Genome Editing Techniques
SEOUL, South Korea, April 18, 2023 /PRNewswire/ -- Until now, most of the major
breakthroughs in the CRISPR field have been led by US academics. Not anymore;
Toolgen, aSouth Korea-based biotech company, has reported three breakthrough
techniques in top-tier scientific journals.
2023-04-18 21:00
1669
Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial
CHENGDU, China, April 18, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 sol...
2023-04-18 21:00
1497
Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma
GUANGZHOU, China, April 18, 2023 /PRNewswire/ -- April 15, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") announced that the Company received IND approval for its second product in the pipeline, a T-cell redirection therapy for the treatment of EBV-positive lymphoma. A week prior to this, t...
2023-04-18 19:03
3482
YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023
FY2023 Revenues Increased by Approximately 30% Year Over Year GAITHERSBURG, Md., April 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new ...
2023-04-18 19:00
2420
Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration
- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening SEOUL, South Korea and NOTTINGHAM, England, April 18, 2023 /PRNewswire/ -- Daewoong Pharmaceuti...
2023-04-18 17:16
2727
GC Biopharma celebrates 'World Hemophilia Day'
* To display a large media façade on its Yong-in R&D Center YONGIN, South Korea, April 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, takes part in a campaign to celebrate World Hemophilia Day. The company announced that a l...
2023-04-18 09:03
1656
Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-18 08:00
2746
Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease
PRINCETON, N.J., April 18, 2023 /PRNewswire/ -- EMJ Nephrology interviewed two World-renowned experts in nephrology and cardiology,George Bakris and Faiez Zannad, regarding the challenges of treating uncontrolled hypertension (uHTN) in patients with advanced chronic kidney disease (CKD), a large ...
2023-04-18 08:00
2148
Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...
2023-04-18 08:00
2903
Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-18 08:00
2200
Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
Promising anti-tumor activity reported for C-CAR031, a novel Glypican 3 (GPC3)-targeting cell therapy designed by AstraZeneca SHANGHAI, April 18, 2023 /PRNewswire/ -- Shanghai Cellular Biopharmaceutical Group Ltd. (the Company, or Shanghai Cellular Bio), a company engaged in the drug development...
2023-04-18 04:15
1926
Promising Efficacy of AT101 CAR-T for Blood Cancer
SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T therapy at the annual 2023 AACR conference. AT101 targets the CD19 protein for treatment of blood cancer. AT101 demonstrated superio...
2023-04-18 02:00
1679
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9236
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7714